ReviewAnnual review of nutrition2023
Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use.
Review in Annual review of nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study.Frontiers in endocrinology · 2025Trial
- Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial.Medicina (Kaunas, Lithuania) · 2024Trial
- Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Dietary diversity in Mediterranean countries is characterized by amino acid and fatty acid profiles.European journal of nutrition · 2026Article
- Development and Characterization of Intravenous Nanoemulsions Loaded withMolecules (Basel, Switzerland) · 2026Article
- Effectiveness of nutrition education program and omega-3 supplementation on body weight, liver enzyme, lipid profile among non-alcoholic fatty liver disease patients.BMC nutrition · 2026Article
- Perilla frutescens seeds enhance lamb immunity and antioxidant capacity via the microbiota-gut-liver-muscle axis.Journal of animal science and biotechnology · 2026Article
- Maternal docosahexaenoic acid and eicosapentaenoic acid supplementation: effects and mechanisms on lipid metabolism in the offspring.Frontiers in nutrition · 2026Review
- ω-3 PUFAs Attenuate Postoperative Ileus by Modulating Macrophage Polarization via the JAK2/STAT3 Signaling Pathway.Journal of inflammation research · 2026Article
- Characterization of the gut virome in patients with nonalcoholic fatty liver disease.Journal of translational medicine · 2025Article
- Higher diet quality is associated with a lower prevalence of MASLD and adverse health outcomes: insights from NHANES 2005 to 2020.European journal of nutrition · 2025Article
- Immunonutrition: Another Player on the MASLD Field.International journal of molecular sciences · 2025Review
- Higher Food Inflammation Index Is Linearly Associated With Higher Risk of MASLD: A Cross-Sectional Study Based on the NHANES (1999-2020).Food science & nutrition · 2025Article
- Mediterranean diet and associated metabolite signatures in relation to MASLD progression: A prospective cohort study.Hepatology communications · 2025Article
- L-Phenylalanine promotes liver steatosis by inhibiting BNIP3-mediated mitophagy.Molecular medicine (Cambridge, Mass.) · 2025Article
- Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD.Nutrients · 2025Review
- Review
- Mesenchymal stem cell-derived small extracellular vesicles reduced hepatic lipid accumulation in MASLD by suppressing mitochondrial fission.Stem cell research & therapy · 2025Article
- Sex-specific effect of dietary fatty acids on non-alcoholic fatty liver disease.Frontiers in nutrition · 2025Article
- Fat-1 Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease and Atherosclerosis through Promoting the Nuclear Localization of PPARα in Hamsters.Research (Washington, D.C.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver disease worldwide, particularly in obese and type 2 diabetic individuals. Currently, there are no therapies for NAFLD that have been approved by the US Food and Drug Administration. Herein, we examine the rationale for using ω3 polyunsaturated fatty acids (PUFAs) in NAFLD therapy. This focus is based on the finding that NAFLD severity is associated with a reduction of hepatic C
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.